Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Melanoma 258Carcinoma, Non-Small-Cell Lung 226Carcinoma, Renal Cell 143Neoplasm Metastasis 97Neoplasms 93Carcinoma, Hepatocellular 85Squamous Cell Carcinoma of Head and Neck 84Colorectal Neoplasms 81Lung Neoplasms 73Stomach Neoplasms 56Pancreatic Neoplasms 56Carcinoma, Transitional Cell 49Hodgkin Disease 47Urinary Bladder Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Head and Neck Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Brain Neoplasms 32Recurrence 27Kidney Neoplasms 27Multiple Myeloma 25Uveal Melanoma 23Esophageal Neoplasms 23Uterine Cervical Neoplasms 22Skin Neoplasms 22

Interventions

Cisplatin 8Carboplatin 8Bevacizumab 8Pleurodesis 7Talc 6Paclitaxel 6Docetaxel 5Povidone-Iodine 4Doxycycline 4Taxes 3Gemcitabine 3Drug Therapy 3Chest Tubes 3aldesleukin 2Zoledronic Acid 2Trastuzumab 2Thoracoscopy 2Sodium Chloride 2Silver Nitrate 2Pharmaceutical Preparations 2Nivolumab 2Interleukin-2 2Fluorodeoxyglucose F18 2Fentanyl 2Erlotinib Hydrochloride 2Cetuximab 2Bortezomib 2viscum album peptide 1tocilizumab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pleural Effusion, Malignant × Nivolumab × Clear all
NCT04749602 2023-03-08

Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.

Kidney Cancer Research Bureau

Phase 2 Completed
26 enrolled
Thoracic

Pleural Effusion, Malignant

NCT03597009 2021-04-20

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
1 enrolled 12 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡